In the pivotal ALSYMPCA study, 1 in m CRPC patients median duration of Ra-223 treatment was 20.1 weeks. Results of the effect of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)

**BACKGROUND**

Radium-223 dichloride (Ra-223) 
- In the pivotal ALSYMPCA study, 1 in m CRPC patients median duration of Ra-223 treatment was 20.1 weeks. Results of the effect of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)

**RESULTS**

**Patients**
- 696 patients were included from 113 sites in 14 countries (Europe, the Americas, and Australia) and received ≥1 dose of Ra-223 (safety population).
- In this study concomitant use was defined as any agent started after the first injection of Ra-223 (concurrent) or started prior to the first injection of Ra-223 and continued during Ra-223 treatment (continuous).

**Use of new endocrine agents in the iEAP**
- The use of new endocrine agents in the iEAP was shown to be as effective as in the ALSYMPCA study with no new safety concerns reported for patients treated in everyday practice.

**OBJECTIVE**
- To investigate safety and OS in patients receiving Ra-223 with concomitant abiraterone and/or enzalutamide in a post hoc analysis of iEAP data.

**PATIENTS AND METHODS**
- The iEAP was a phase 3b single-arm, international, prospective, intermittent, open-label multicenter EAP (Figure 1).

**RESULTS**
- In total 189 Ra-223 treated patients received concomitant abiraterone and/or enzalutamide—15 patients were treated concurrently with both abiraterone and enzalutamide.

**CONCLUSIONS**
- Ra-223 administered with either abiraterone and/or enzalutamide was generally well tolerated in mCRPC patients with bone metastases, with no new safety signals reported.
- OS appeared to be longer in patients receiving Ra-223 with concomitant novel endocrine agents than in those treated with Ra-223 without these agents.
- Studies are ongoing to prospectively assess the safety and efficacy of these treatment combinations.

**REFERENCES**

**ACKNOWLEDGEMENTS**
- The study was sponsored by Bayer HealthCare AG.
- Medical writing assistance was provided by Dr Paul Hoban, of Cancer Communications and Consulting Ltd, Knutsford, UK and funded by Bayer HealthCare AG.